Why Is Buffett Buying Verisign?
Warren Buffett has spent 2024 stockpiling cash, even going so…
Sell
49
TNXP Quote, Financials, Valuation and Earnings
Last price:
$0.34
Seasonality move
:
8.91%
Day range:
$0.31 - $0.35
52-week range:
$0.12 - $14.08
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.53x
P/B ratio:
0.85x
Volume:
73.1M
Avg. volume:
143.2M
1-year change:
-97.46%
Market cap:
$63.1M
Revenue:
$7.8M
EPS (TTM):
-$101.00
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TNXP
Tonix Pharmaceuticals Holding
|
$3.2M | -$7.36 | -15.32% | -89.86% | $5.83 |
|
ABT
Abbott Laboratories
|
$10.6B | $1.20 | 7.79% | 47.49% | $130.20 |
|
CMRX
Chimerix
|
$312K | -$0.24 | 7665% | -35.71% | -- |
|
EBS
Emergent BioSolutions
|
$297.5M | $0.14 | -4.04% | -32.63% | $12.00 |
|
FOLD
Amicus Therapeutics
|
$135M | $0.05 | 28.06% | -81.83% | -- |
|
GOVX
Geovax Labs
|
$1.3M | -- | -- | -- | $14.60 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TNXP
Tonix Pharmaceuticals Holding
|
$0.34 | $5.83 | $63.1M | -- | $0.00 | 0% | 0.53x |
|
ABT
Abbott Laboratories
|
$114.99 | $130.20 | $199.4B | 34.95x | $0.55 | 1.91% | 4.88x |
|
CMRX
Chimerix
|
$3.46 | -- | $311.2M | -- | $0.00 | 0% | -- |
|
EBS
Emergent BioSolutions
|
$8.27 | $12.00 | $448.1M | -- | $0.00 | 0% | 0.40x |
|
FOLD
Amicus Therapeutics
|
$9.63 | -- | $2.9B | -- | $0.00 | 0% | 5.91x |
|
GOVX
Geovax Labs
|
$2.46 | $14.60 | $23.2M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TNXP
Tonix Pharmaceuticals Holding
|
9.72% | 0.642 | 34.58% | 2.52x |
|
ABT
Abbott Laboratories
|
27.35% | 0.747 | 8.05% | 1.14x |
|
CMRX
Chimerix
|
-- | 0.928 | -- | 6.13x |
|
EBS
Emergent BioSolutions
|
56.58% | 10.051 | 146.79% | 1.18x |
|
FOLD
Amicus Therapeutics
|
68.53% | 1.122 | 12.21% | 2.20x |
|
GOVX
Geovax Labs
|
-- | 5.640 | -- | 3.50x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TNXP
Tonix Pharmaceuticals Holding
|
$1.3M | -$13.9M | -139.38% | -150.01% | -492.06% | -$18.8M |
|
ABT
Abbott Laboratories
|
$5.9B | $1.9B | 10.69% | 14.78% | 19.58% | $2.1B |
|
CMRX
Chimerix
|
-- | -$24.8M | -48.21% | -48.22% | -95357.69% | -$20.5M |
|
EBS
Emergent BioSolutions
|
$161.2M | $64.5M | -14.79% | -35.94% | 53.1% | $147.9M |
|
FOLD
Amicus Therapeutics
|
$128.2M | $24.8M | -19.5% | -71.17% | 13.76% | -$23.3M |
|
GOVX
Geovax Labs
|
-- | -$5.9M | -571.64% | -575.49% | -207.97% | -$9.3M |
Tonix Pharmaceuticals Holding vs. Competitors
-
Which has Higher Returns TNXP or ABT?
Abbott Laboratories has a net margin of -503.65% compared to Tonix Pharmaceuticals Holding's net margin of 15.48%. Tonix Pharmaceuticals Holding's return on equity of -150.01% beat Abbott Laboratories's return on equity of 14.78%.
Company Gross Margin Earnings Per Share Invested Capital TNXPTonix Pharmaceuticals Holding44.9% -$0.23 $82.2M ABTAbbott Laboratories55.83% $0.94 $55B -
What do Analysts Say About TNXP or ABT?
Tonix Pharmaceuticals Holding has a consensus price target of $5.83, signalling upside risk potential of 1627.88%. On the other hand Abbott Laboratories has an analysts' consensus of $130.20 which suggests that it could grow by 13.23%. Given that Tonix Pharmaceuticals Holding has higher upside potential than Abbott Laboratories, analysts believe Tonix Pharmaceuticals Holding is more attractive than Abbott Laboratories.
Company Buy Ratings Hold Ratings Sell Ratings TNXPTonix Pharmaceuticals Holding2 0 0 ABTAbbott Laboratories13 5 0 -
Is TNXP or ABT More Risky?
Tonix Pharmaceuticals Holding has a beta of 2.232, which suggesting that the stock is 123.214% more volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.727, suggesting its less volatile than the S&P 500 by 27.271%.
-
Which is a Better Dividend Stock TNXP or ABT?
Tonix Pharmaceuticals Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abbott Laboratories offers a yield of 1.91% to investors and pays a quarterly dividend of $0.55 per share. Tonix Pharmaceuticals Holding pays -- of its earnings as a dividend. Abbott Laboratories pays out 62.14% of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TNXP or ABT?
Tonix Pharmaceuticals Holding quarterly revenues are $2.8M, which are smaller than Abbott Laboratories quarterly revenues of $10.6B. Tonix Pharmaceuticals Holding's net income of -$14.2M is lower than Abbott Laboratories's net income of $1.6B. Notably, Tonix Pharmaceuticals Holding's price-to-earnings ratio is -- while Abbott Laboratories's PE ratio is 34.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding is 0.53x versus 4.88x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNXPTonix Pharmaceuticals Holding0.53x -- $2.8M -$14.2M ABTAbbott Laboratories4.88x 34.95x $10.6B $1.6B
-
Which has Higher Returns TNXP or CMRX?
Chimerix has a net margin of -503.65% compared to Tonix Pharmaceuticals Holding's net margin of -87996.15%. Tonix Pharmaceuticals Holding's return on equity of -150.01% beat Chimerix's return on equity of -48.22%.
Company Gross Margin Earnings Per Share Invested Capital TNXPTonix Pharmaceuticals Holding44.9% -$0.23 $82.2M CMRXChimerix-- -$0.26 $135.8M -
What do Analysts Say About TNXP or CMRX?
Tonix Pharmaceuticals Holding has a consensus price target of $5.83, signalling upside risk potential of 1627.88%. On the other hand Chimerix has an analysts' consensus of -- which suggests that it could grow by 142.78%. Given that Tonix Pharmaceuticals Holding has higher upside potential than Chimerix, analysts believe Tonix Pharmaceuticals Holding is more attractive than Chimerix.
Company Buy Ratings Hold Ratings Sell Ratings TNXPTonix Pharmaceuticals Holding2 0 0 CMRXChimerix5 0 0 -
Is TNXP or CMRX More Risky?
Tonix Pharmaceuticals Holding has a beta of 2.232, which suggesting that the stock is 123.214% more volatile than S&P 500. In comparison Chimerix has a beta of 1.018, suggesting its more volatile than the S&P 500 by 1.827%.
-
Which is a Better Dividend Stock TNXP or CMRX?
Tonix Pharmaceuticals Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Chimerix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tonix Pharmaceuticals Holding pays -- of its earnings as a dividend. Chimerix pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNXP or CMRX?
Tonix Pharmaceuticals Holding quarterly revenues are $2.8M, which are larger than Chimerix quarterly revenues of $26K. Tonix Pharmaceuticals Holding's net income of -$14.2M is higher than Chimerix's net income of -$22.9M. Notably, Tonix Pharmaceuticals Holding's price-to-earnings ratio is -- while Chimerix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding is 0.53x versus -- for Chimerix. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNXPTonix Pharmaceuticals Holding0.53x -- $2.8M -$14.2M CMRXChimerix-- -- $26K -$22.9M
-
Which has Higher Returns TNXP or EBS?
Emergent BioSolutions has a net margin of -503.65% compared to Tonix Pharmaceuticals Holding's net margin of 40.45%. Tonix Pharmaceuticals Holding's return on equity of -150.01% beat Emergent BioSolutions's return on equity of -35.94%.
Company Gross Margin Earnings Per Share Invested Capital TNXPTonix Pharmaceuticals Holding44.9% -$0.23 $82.2M EBSEmergent BioSolutions56.8% $2.06 $1.2B -
What do Analysts Say About TNXP or EBS?
Tonix Pharmaceuticals Holding has a consensus price target of $5.83, signalling upside risk potential of 1627.88%. On the other hand Emergent BioSolutions has an analysts' consensus of $12.00 which suggests that it could grow by 45.1%. Given that Tonix Pharmaceuticals Holding has higher upside potential than Emergent BioSolutions, analysts believe Tonix Pharmaceuticals Holding is more attractive than Emergent BioSolutions.
Company Buy Ratings Hold Ratings Sell Ratings TNXPTonix Pharmaceuticals Holding2 0 0 EBSEmergent BioSolutions1 0 0 -
Is TNXP or EBS More Risky?
Tonix Pharmaceuticals Holding has a beta of 2.232, which suggesting that the stock is 123.214% more volatile than S&P 500. In comparison Emergent BioSolutions has a beta of 1.594, suggesting its more volatile than the S&P 500 by 59.352%.
-
Which is a Better Dividend Stock TNXP or EBS?
Tonix Pharmaceuticals Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Emergent BioSolutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tonix Pharmaceuticals Holding pays -- of its earnings as a dividend. Emergent BioSolutions pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNXP or EBS?
Tonix Pharmaceuticals Holding quarterly revenues are $2.8M, which are smaller than Emergent BioSolutions quarterly revenues of $283.8M. Tonix Pharmaceuticals Holding's net income of -$14.2M is lower than Emergent BioSolutions's net income of $114.8M. Notably, Tonix Pharmaceuticals Holding's price-to-earnings ratio is -- while Emergent BioSolutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding is 0.53x versus 0.40x for Emergent BioSolutions. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNXPTonix Pharmaceuticals Holding0.53x -- $2.8M -$14.2M EBSEmergent BioSolutions0.40x -- $283.8M $114.8M
-
Which has Higher Returns TNXP or FOLD?
Amicus Therapeutics has a net margin of -503.65% compared to Tonix Pharmaceuticals Holding's net margin of -4.76%. Tonix Pharmaceuticals Holding's return on equity of -150.01% beat Amicus Therapeutics's return on equity of -71.17%.
Company Gross Margin Earnings Per Share Invested Capital TNXPTonix Pharmaceuticals Holding44.9% -$0.23 $82.2M FOLDAmicus Therapeutics90.62% -$0.02 $568.3M -
What do Analysts Say About TNXP or FOLD?
Tonix Pharmaceuticals Holding has a consensus price target of $5.83, signalling upside risk potential of 1627.88%. On the other hand Amicus Therapeutics has an analysts' consensus of -- which suggests that it could grow by 79.99%. Given that Tonix Pharmaceuticals Holding has higher upside potential than Amicus Therapeutics, analysts believe Tonix Pharmaceuticals Holding is more attractive than Amicus Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings TNXPTonix Pharmaceuticals Holding2 0 0 FOLDAmicus Therapeutics0 0 0 -
Is TNXP or FOLD More Risky?
Tonix Pharmaceuticals Holding has a beta of 2.232, which suggesting that the stock is 123.214% more volatile than S&P 500. In comparison Amicus Therapeutics has a beta of 0.599, suggesting its less volatile than the S&P 500 by 40.114%.
-
Which is a Better Dividend Stock TNXP or FOLD?
Tonix Pharmaceuticals Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tonix Pharmaceuticals Holding pays -- of its earnings as a dividend. Amicus Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNXP or FOLD?
Tonix Pharmaceuticals Holding quarterly revenues are $2.8M, which are smaller than Amicus Therapeutics quarterly revenues of $141.5M. Tonix Pharmaceuticals Holding's net income of -$14.2M is lower than Amicus Therapeutics's net income of -$6.7M. Notably, Tonix Pharmaceuticals Holding's price-to-earnings ratio is -- while Amicus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding is 0.53x versus 5.91x for Amicus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNXPTonix Pharmaceuticals Holding0.53x -- $2.8M -$14.2M FOLDAmicus Therapeutics5.91x -- $141.5M -$6.7M
-
Which has Higher Returns TNXP or GOVX?
Geovax Labs has a net margin of -503.65% compared to Tonix Pharmaceuticals Holding's net margin of -208.48%. Tonix Pharmaceuticals Holding's return on equity of -150.01% beat Geovax Labs's return on equity of -575.49%.
Company Gross Margin Earnings Per Share Invested Capital TNXPTonix Pharmaceuticals Holding44.9% -$0.23 $82.2M GOVXGeovax Labs-- -$0.91 $8.5M -
What do Analysts Say About TNXP or GOVX?
Tonix Pharmaceuticals Holding has a consensus price target of $5.83, signalling upside risk potential of 1627.88%. On the other hand Geovax Labs has an analysts' consensus of $14.60 which suggests that it could grow by 493.5%. Given that Tonix Pharmaceuticals Holding has higher upside potential than Geovax Labs, analysts believe Tonix Pharmaceuticals Holding is more attractive than Geovax Labs.
Company Buy Ratings Hold Ratings Sell Ratings TNXPTonix Pharmaceuticals Holding2 0 0 GOVXGeovax Labs3 0 0 -
Is TNXP or GOVX More Risky?
Tonix Pharmaceuticals Holding has a beta of 2.232, which suggesting that the stock is 123.214% more volatile than S&P 500. In comparison Geovax Labs has a beta of 3.242, suggesting its more volatile than the S&P 500 by 224.241%.
-
Which is a Better Dividend Stock TNXP or GOVX?
Tonix Pharmaceuticals Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geovax Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tonix Pharmaceuticals Holding pays -- of its earnings as a dividend. Geovax Labs pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNXP or GOVX?
Tonix Pharmaceuticals Holding quarterly revenues are $2.8M, which are larger than Geovax Labs quarterly revenues of $2.8M. Tonix Pharmaceuticals Holding's net income of -$14.2M is lower than Geovax Labs's net income of -$5.8M. Notably, Tonix Pharmaceuticals Holding's price-to-earnings ratio is -- while Geovax Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding is 0.53x versus -- for Geovax Labs. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNXPTonix Pharmaceuticals Holding0.53x -- $2.8M -$14.2M GOVXGeovax Labs-- -- $2.8M -$5.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Microsoft an Undervalued Growth Stock to Buy?
Tech giant Microsoft (NASDAQ:MSFT) has been one of the biggest…
Will Tesla Go Up or Down in 2025?
The last few months have been exciting for Tesla and…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
54
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
LMND alert for Dec 30
Lemonade [LMND] is down 1.85% over the past day.
Sell
50
TSLL alert for Dec 30
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 5.09% over the past day.
Buy
63
SMLR alert for Dec 30
Semler Scientific [SMLR] is down 9.09% over the past day.
